HDAC inhibitors for the treatment of cutaneous T-cell lymphomas

Future Medicinal Chemistry

Volumn 4, Issue 4, 2012, Pages 471-486

  Rangwala, Sophia ^a   Zhang, Chunlei ^a   Duvic, Madeleine ^a  

^a University of Texas Health Science Center at Houston   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BELINOSTAT; BEXAROTENE; BIOLOGICAL MARKER; BORTEZOMIB; CYTOKINE; DEPSIPEPTIDE; ETOPOSIDE; EVEROLIMUS; FENOFIBRATE; GAMMA INTERFERON; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; NICOTINAMIDE; PANOBINOSTAT; ROMIDEPSIN; STAT PROTEIN; VORINOSTAT;

ANGIOGENESIS; APOPTOSIS; CANCER RELAPSE; CANCER STAGING; CUTANEOUS T CELL LYMPHOMA; DRUG ANTAGONISM; DRUG POTENTIATION; EPIGENETICS; FATIGUE; FOOD AND DRUG ADMINISTRATION; HUMAN; LYMPHOMA; MULTIPLE MYELOMA; MYCOSIS FUNGOIDES; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEZARY SYNDROME; T CELL LYMPHOMA; THROMBOCYTOPENIA; TREATMENT RESPONSE; UPREGULATION; VOMITING;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; EPIGENESIS, GENETIC; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; SKIN NEOPLASMS;

EID: 84863367140     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.6     Document Type: Review

References (93)

1. Criscione VD, Weinstock MA. Incidence of cutaneous T cell lymphoma in the United States, 1973-2002. Arch. Dermatol. 143(7), 854-859 (2007). (Pubitemid 47076482)
2. Campbell JJ, Clark RA, Watanabe R, Kupper TS. Sezary syndrome and mycosis fungoides arise from distinct T cell subsets: a biologic rationale for their distinct clinical behaviors. Blood 116(5), 767-771 (2010).
3. Duvic M, Foss FM. Mycosis fungoides: pathophysiology and emerging therapies. Semin. Oncol. 34(6 Suppl. 5), S21-S28 (2007). (Pubitemid 350250800)
4. Olsen EA, Rook AH, Zic J et al. Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States cutaneous lymphoma consortium (USCLC). J. Am. Acad. Dermatol. 64(2), 352-404 (2011).
5. Talpur R, Bassett R, Duvic M. Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sezary syndrome. Br. J. Dermatol. 159(1), 105-112 (2008). (Pubitemid 351874496)
6. Demierre MF, Tien A, Miller D. Health related quality-of-life assessment in patients with cutaneous T cell lymphoma. Arch. Dermatol. 141(3), 325-330 (2005). (Pubitemid 40365448)
7. Duvic M, Talpur R, Ni X et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T cell lymphoma (CTCL). Blood 109(1), 31-39 (2007). (Pubitemid 46053039)
8. Vidulich KA, Talpur R, Bassett RL, Duvic M. Overall survival in erythrodermic cutaneous T cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T cell lymphoma. Int. J. Dermatol. 48(3), 243-252 (2009).
9. Jackow CM, McHam JB, Friss A, Alvear J, Reveille JR, Duvic M. HLA-DR5 and DQB1.*03 Class 2 alleles are associated with cutaneous T cell lymphoma. J. Invest. Dermatol. 107(3), 373-376 (1996). (Pubitemid 26284346)
10. Ni X, Zhang C, Talpur R, Duvic M. Resistance to activation-induced cell death and bystander cytotoxicity via the Fas/Fas ligand pathway are implicated in the pathogenesis of cutaneous T cell lymphomas. J. Invest. Dermatol. 124(4), 741-750 (2005). (Pubitemid 40489501)
11. Whittemore AS, Holly EA, Lee IM et al. Mycosis fungoides in relation to environmental exposures and immune response: a case-control study. J. Natl Cancer Inst. 81(20), 1560-1567 (1989). (Pubitemid 19253304)
12. Mirvish ED, Pomerantz RG, Geskin LJ. Infectious agents in cutaneous T cell lymphoma. J. Am. Acad. Dermatol. 64(2), 423-431 (2011).
13. Vega F, Luthra R, Medeiros LJ et al. Clonal heterogeneity in mycosis fungoides and its relationship to clinical course. Blood 100(9), 3369-3373 (2002). (Pubitemid 35217089)
14. Berger CL, Hanlon D, Kanada D et al. The growth of cutaneous T cell lymphoma is stimulated by immature dendritic cells. Blood 99(8), 2929-2939 (2002). (Pubitemid 34525383)
15. Kacinski BM, Flick M. Apoptosis and cutaneous T cell lymphoma. Annu. NY. Acad. Sci. 941, 194-199 (2001). (Pubitemid 32928346)
16. Kim EJ, Hess S, Richardson SK et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J. Clin. Invest. 115(4), 798-812 (2005). (Pubitemid 40489380)
17. Duvic M, Hymes K, Heald P et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T cell lymphoma: multinational Phase II-III trial results. J. Clin. Oncol. 19(9), 2456-2471 (2001). (Pubitemid 32391217)
18. Piekarz RL, Frye R, Turner M et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T cell lymphoma. J. Clin. Oncol. 27(32), 5410-5417 (2009).
19. Duvic M, Donato M, Dabaja B et al. Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome. J. Clin. Oncol. 28(14), 2365-2372 (2010).
20. Duvic M. Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies. Oncology (Williston Park). 21(2 Suppl. 1), 33-40 (2007).
21. Olsen EA, Kim YH, Kuzel TM et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J. Clin. Oncol. 25(21), 3109-3115 (2007). (Pubitemid 47218059)
22. Beumer JH, Tawbi H. Role of histone deacetylases and their inhibitors in cancer biology and treatment. Curr. Clin. Pharmacol. 5(3), 196-208 (2010).
23. Ellis L, Pili R. Histone deacetylase inhibitors: advancing therapeutic strategies in hematological and solid malignancies. Pharmaceuticals (Basel) 3(8), 2411-2469 (2010).
24. Lemoine M, Younes A. Histone deacetylase inhibitors in the treatment of lymphoma. Discov. Med. 10(54), 462-470 (2010).
25. Marquard L, Gjerdrum LM, Christensen IJ, Jensen PB, Sehested M, Ralfkiaer E. Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T cell lymphoma. Histopathology 53(3), 267-277 (2008).
26. Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett. 280(2), 168-176 (2009).
27. Peart MJ, Smyth GK, Van Laar RK et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc. Natl Acad. Sci. USA 102(10), 3697-3702 (2005). (Pubitemid 40354674)
28. Choudhary C, Kumar C, Gnad F et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325(5942), 834-840 (2009).
29. Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: overview and perspectives. Mol. Cancer Res. 5(10), 981-989 (2007). (Pubitemid 350080267)
30. Zain J, O'Connor OA. Targeting histone deacetyalses in the treatment of B- and T cell malignancies. Invest. New Drugs 28(Suppl. 1), S58-S78 (2010).
31. Sambucetti LC, Fischer DD, Zabludoff S et al. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J. Biol. Chem. 274(49), 34940-34947 (1999). (Pubitemid 129509542)
32. Sandor V, Senderowicz A, Mertins S et al. P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br. J. Cancer. 83(6), 817-825 (2000).
33. Zhang C, Richon V, Ni X, Talpur R, Duvic M. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T cell lymphoma cells: relevance to mechanism of therapeutic action. J. Invest. Dermatol. 125(5), 1045-1052 (2005).
34. Emanuele S, Lauricella M, Tesoriere G. Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review). Int. J. Oncol. 33(4), 637-646 (2008).
35. Nalabothula N, Carrier F. Cancer cells' epigenetic composition and predisposition to histone deacetylase inhibitor sensitization. Epigenomics 3(2), 145-155 (2011).
36. Ellis L, Bots M, Lindemann RK et al. The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy. Blood 114(2), 380-393 (2009).
37. Shao W, Growney JD, Feng Y et al. Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T cell lymphoma models: defining molecular mechanisms of resistance. Int. J. Cancer 127(9), 2199-2208 (2010).
38. Shao Y, Gao Z, Marks PA, Jiang X. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc. Natl Acad. Sci. USA 101(52), 18030-18035 (2004). (Pubitemid 40054069)
39. Droin N, Guery L, Benikhlef N, Solary E. Targeting apoptosis proteins in hematological malignancies. Cancer Lett. 30, 30 doi:10.1016/j.canlet.2011.06.016 (2011) (Epub ahead of print).
40. Robert T, Vanoli F, Chiolo I et al. HDACs link the DNA damage response, processing of double-strand breaks and autophagy. Nature 471(7336), 74-79 (2011).
41. Kwon HJ, Kim MS, Kim MJ, Nakajima H, Kim KW. Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis. Int. J. Cancer 97(3), 290-296 (2002). (Pubitemid 34049018)
42. Qian DZ, Kato Y, Shabbeer S et al. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin. Cancer Res. 12(2), 634-642 (2006). (Pubitemid 43166159)
43. Grabiec AM, Tak PP, Reedquist KA. Function of histone deacetylase inhibitors in inflammation. Crit. Rev. Immunol. 31(3), 233-263 (2011).
44. Duvic M, Vanaclocha F, Bernengo MG et al. Phase II study of oral panobinostat (LBH589), a potent pan-deacetylase inhibitor, in patients with refractory cutaneous T cell lymphoma (CTCL). Presented at: ASCO American Society of Clinical Oncology Meeting. Chicago, IL, USA, 20 May 2008 (Poster 8555).
45. Pohlman B, Advani R, Duvic M et al. Final results of a Phase II trial of belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T cell lymphoma. Presented at: ASH Annual Meeting and Expositions. New Orleans, LA, USA, 8 December 2009 (Poster 3453).
46. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat. Biotechnol. 25(1), 84-90 (2007). (Pubitemid 46087907)
47. Kelly WK, Marks PA. Drug insight: histone deacetylase inhibitors - development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat. Clin. Pract. Oncol. 2(3), 150-157 (2005). (Pubitemid 40823166)
48. Bradner JE, West N, Grachan ML et al. Chemical phylogenetics of histone deacetylases. Nat. Chem. Biol. 6(3), 238-243 (2010).
49. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol. 27(32), 5459-5468 (2009).
50. Ruefli AA, Ausserlechner MJ, Bernhard D et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc. Natl Acad. Sci. USA 98(19), 10833-10838 (2001). (Pubitemid 32878706)
51. Lee JH, Choy ML, Ngo L, Foster SS, Marks PA. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc. Natl Acad. Sci. USA 107(33), 14639-14644 (2010).
52. Kelly WK, O'Connor OA, Krug LM et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol. 23(17), 3923-3931 (2005). (Pubitemid 46218695)
53. Gui CY, Ngo L, Xu WS, Richon VM, Marks PA. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc. Natl Acad. Sci. USA 101(5), 1241-1246 (2004). (Pubitemid 38182673)
54. Tait SW, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat. Rev. Mol. Cell Biol. 11(9), 621-632 (2010).
55. Qin JZ, Zhang CL, Kamarashev J, Dummer R, Burg G, Dobbeling U. Interleukin-7 and interleukin-15 regulate the expression of the bcl-2 and c-myb genes in cutaneous T cell lymphoma cells. Blood 98(9), 2778-2783 (2001).
56. Fantin VR, Loboda A, Paweletz CP et al. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T cell lymphoma. Cancer Res. 68(10), 3785-3794 (2008).
57. Tiffon C, Adams J, Van der Fits L et al. The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expressionin cutaneous T-cell lymphoma cells. Br. J. Pharmacol. 162(7), 1590-1602 (2011).
58. Cao Y. Molecular mechanisms and therapeutic development of angiogenesis inhibitors. Adv. Cancer Res. 100, 113-131 (2008). (Pubitemid 351932181)
59. Fotheringham S, Epping MT, Stimson L et al. Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cell 15(1), 57-66 (2009).
60. Khan O, Fotheringham S, Wood V et al. HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proc. Natl Acad. Sci. USA 107(14), 6532-6537 (2010).
61. Duvic M, Olsen EA, Breneman D et al. Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T cell lymphoma. Clin. Lymphoma Myeloma 9(6), 412-416 (2009).
62. O'Connor OA, Heaney ML, Schwartz L et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J. Clin. Oncol. 24(1), 166-173 (2006). (Pubitemid 46630509)
63. Nakajima H, Kim YB, Terano H, Yoshida M, Horinouchi S. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp. Cell Res. 241(1), 126-133 (1998). (Pubitemid 28366586)
64. Furumai R, Matsuyama A, Kobashi N et al. FK228 (depsipeptide) as a natural prodrug that inhibits Class 1 histone deacetylases. Cancer Res. 62(17), 4916-4921 (2002). (Pubitemid 34984414)
65. Piekarz RL, Robey RW, Zhan Z et al. T cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood 103(12), 4636-4643 (2004). (Pubitemid 38745996)
66. Marshall JL, Rizvi N, Kauh J et al. A Phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J. Exp. Ther. Oncol. 2(6), 325-332 (2002). (Pubitemid 35265981)
67. Piekarz RL, Robey R, Sandor V et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T cell lymphoma: a case report. Blood 98(9), 2865-2868 (2001).
68. Whittaker SJ, Demierre MF, Kim EJ et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T cell lymphoma. J. Clin. Oncol. 28(29), 4485-4491 (2010).
69. Shah MH, Binkley P, Chan K et al. Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors. Clin. Cancer Res. 12(13), 3997-4003 (2006). (Pubitemid 44078086)
70. Sandor V, Bakke S, Robey RW et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin. Cancer Res. 8(3), 718-728 (2002). (Pubitemid 34742100)
71. Bates SE, Zhan Z, Steadman K et al. Laboratory correlates for a Phase II trial of romidepsin in cutaneous and peripheral T cell lymphoma. Br. J. Haematol. 148(2), 256-267 (2010).
72. Steele NL, Plumb JA, Vidal L et al. Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101). Cancer Chemother. Pharmacol. 67(6), 1273-1279 (2011).
73. Plumb JA, Finn PW, Williams RJ et al. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol. Cancer Ther. 2(8), 721-728 (2003).
74. Chowdhury S, Howell GM, Teggart CA et al. The histone deacetylase inhibitor belinostat represses survivin expression through reactivation of TGF{b} receptor II leading to cancer cell death. J. Biol. Chem. 286(35), 30937-30948 (2011).
75. Lassen U, Molife LR, Sorensen M et al. A Phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours. Br. J. Cancer. 103(1), 12-17 (2010).
76. Steele NL, Plumb JA, Vidal L et al. A Phase I pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin. Cancer Res. 14(3), 804-810 (2008). (Pubitemid 351231163)
77. Gimsing P, Hansen M, Knudsen LM et al. A Phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. Eur. J. Haematol. 81(3), 170-176 (2008).
78. Prince HM, Bishton MJ, Johnstone RW. Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncol. 5(5), 601-612 (2009).
79. Chen J, Fiskus W, Eaton K et al. Cotreatment with BCL-2 antagonist sensitizes cutaneous T cell lymphoma to lethal action of HDAC7-Nur77-based mechanism. Blood 113(17), 4038-4048 (2009).
80. Ellis L, Pan Y, Smyth GK et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T cell lymphoma. Clin. Cancer Res. 14(14), 4500-4510 (2008).
81. Cheriyath V, Kuhns MA, Kalaycio ME, Borden EC. Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma. Br. J. Cancer 104(6), 957-967 (2011).
82. Terpos E. The synergistic effect of panobinostat (LBH589) with melphalan or doxorubicin on multiple myeloma cells; rationale for the use of combination regimens in myeloma patients. Leuk. Res. 35(3), 295-296 (2011).
83. Bellos F, Mahlknecht U. Valproic acid and all-trans-retinoic acid: meta-analysis of a palliative treatment regimen in AML and MDS patients. Onkologie 31(11), 629-633 (2008).
84. Page P, Yang LX. Novel chemoradiosensitizers for cancer therapy. Anticancer Res. 30(9), 3675-3682 (2010).
85. Dummer R, Hymes K, Sterry W et al. Vorinostat in combination with bexarotene in advanced cutaneous T cell lymphoma: a Phase I study. Presented at: ASCO American Society of Clinical Oncology Meeting. Orlando, FL, USA, 20 May 2009 (Poster 8572).
86. Steinhoff M, Beyer M, Roewert-Huber J et al. Complete clinical remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofibrate. J. Am. Acad. Dermatol. 58(5 Suppl. 1), S88-S91 (2008). (Pubitemid 351503635)
87. Gardner JM, Introcaso CE, Nasta SD, Kim EJ, Vittorio CC, Rook AH. A novel regimen of vorinostat with interferon g for refractory Sezary syndrome. J. Am. Acad. Dermatol. 61(1), 112-116 (2009).
88. Sanli H, Akay BN, Anadolu R, Ozcan M, Saral S, Akyol A. The efficacy of vorinostat in combination with interferon alpha and extracorporeal photopheresis in late stage mycosis fungoides and Sézary syndrome. J. Drugs Dermatol. 10(4), 403-408 (2011).
89. Heider U, Rademacher J, Lamottke B et al. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma. Eur. J. Haematol. 82(6), 440-449 (2009).
90. Zhang QL, Wang L, Zhang YW et al. The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis. Leukemia 23(8), 1507-1514 (2009).
91. Wozniak MB, Villuendas R, Bischoff JR et al. Vorinostat interferes with the signaling transduction pathway of T cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T cell lymphoma. Haematologica 95(4), 613-621 (2010).
92. Karagiannis TC, El-Osta A. Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds? Leukemia 21(1), 61-65 (2007). (Pubitemid 44921835)
93. Zhang CL, Duvic M. Benefits of vorinostat in treating advanced cutaneous T-cell lymphoma. US Oncol. 5(1), 27-31 (2009).